Wed 7 May
0745 - 0845
ABN Committee Meetings (5 EDI, 6 Quality, 8 Research, 9 Education, 10 Services)
0900 - 0915
0915 - 1015
1A Opening & Welcome: Richard Davenport, Edinburgh
1A Plenary Session 1: Pathogenic Mechanisms in Neurological Disorders
Chairs: Ruth Dobson & James Lilleker
0915 Mitochondrial disease in adults: Recent advances and future promise: Yi Ng, Royal Victoria Infirmary, Newcastle
0945 Oligodendrocyte biology and MS: Denise Fitzgerald, Queen’s University, Belfast
1015 - 1100
1A ABN Practical Neurology Lecture 2025
Chairs: Phil Smith & Geraint Fuller
Alcohol consumption after stroke-abstinence or moderation: Karen Furie, Rhode Island Hospital, USA
1100 - 1145
2A Coffee & Exhibition
Teva Silent Symposium: Optimising Neurology for Migraine: Enhancing Best Practice and Reducing Waiting Lists
1145 - 1255
Parallel Sessions
1A Parallel Session 1: Epilepsy
Chairs: Owen Pickrell & Tony Marson
1145 ABN Fellow presentation: Interoception as a diagnostic, mechanistic and therapeutic prism for functional seizures: Rohan Kandasamy
1156 Hypophosphataemia as a Potential Biological Marker in Seizure Diagnosis: A Retrospective Analysis: Ammar Abdelaziz
1207 Predicting the emergence of seizures in acquired brain injury patients weaning off anti-seizure medication: Marcus Chan
1218 Preictal aperiodic activity in EEG shows changes specific to seizure regions: Rohan Kandasamy
1229 Dose Adjustments of Lamotrigine During Pregnancy and the Postpartum Period: Lina Nashef
1240 Toclizumab for RSE in those with or without pre-existing epilepsy – Time for a trial? Asha Patel
1B Parallel Session 2: Cognitive
Chairs: Simon Bell & Tom Massey
1145 ABN Fellow presentation: Performance of Alzheimer’s disease plasma biomarkers in prion diseases: Thomas Coysh
1156 Repurposed Drug Prioritisation Pipeline for an Alzheimer’s Disease Multi-arm Trial: Sabahat Iqbal
1207 Brain DNA methylation age, lifestyle factors and dementia in the Swedish Twin Registry: Chris McMurran
1218 Generalisable MRI-based normative modelling for detecting age-inappropriate neurodegeneration: Thomas Parker
1229 Amyloid Presence in Thrombi Retrieved from Acute Ischemic Stroke Patients: Implications for Fibrinolytic Resistance: Alakendu Sekhar
1240 Acoustic speech analysis and machine learning in the diagnosis and monitoring of neurodegenerative disorders: Johnny Tam
1255 - 1425
Lunch, Exhibition & Sponsored Symposia
1310 – 1410
Sponsored Symposia sessions:
1B Roche Treatment and innovation improves patient outcomes in MS: A consultant, nurse and patient perspective
1C UCB LGS or LGS-Like. How to decide?
3B AstraZeneca (Amyloid neuropathy)
1425 - 1530
2A Poster Session 1
Group 1: Vascular/Oncology
Chairs: Elina Melikyan & Ann Donnelly
Group 3: Peripheral Nerve
Chairs: Michael Lunn & Clare Galtrey
Group 5:Infection/ Encephalitis
Chairs: Adam Handel & David McKee
Group 7: Cognitive
Chairs: George Pengas & Rhys Davies
Group 9: MS/Inflammatory
Chairs: Claire Rice & John Woolmore
1530 - 1630
1A Plenary Session 2: Expert Management of Common Neurological Disorders
Chairs: Helen Grote & Khalid Hamandi
1530 The Parkinson’s follow-up: the drugs and beyond for the general neurologist: Chris Kobylecki, Salford Manchester
1600 The epilepsy follow-up: the drugs and beyond for the general neurologist: Gary Dennis, Sheffield
1630 - 1715
2A Coffee & Exhibition
Teva Silent Symposium: Optimising Neurology for Migraine: Enhancing Best Practice and Reducing Waiting Lists
1715 - 1800
1A ABN Medallist Lecture 2025: Channelling a path from muscle through water to brain
Jaqueline Palace, John Radcliffe Hospital, Oxford
Citation: Isabel Maria Leite
1800 - 1900
2A Welcome Reception
Thursday 8 May
0700 - 0740
0745 - 0845
Yoga Session / Waterfront Walk
Special Interest Group Sessions:
1A Epilepsy
1C Neuro infection
3A Peripheral Nerve
3B TBI
0900 - 1000
1A Plenary Session 3: Advice, Management and Referral
Chairs: Lucia Li & Sean Slaught
0900 Managing sleep disorders: Guy Leschziner, Guys and St Thomas’ Hospital, London
0930 Cervical myelopathy: Adrian Casey, NHNN, London
1000 - 1045
2A Coffee, Exhibition & Silent Symposium: Roche
1045 - 1130
1A ABN Gordon Holmes Lecture 2025 – Sponsored by Guarantors of Brain:
A Journey to the Centre of the Chiasm. Christian Lueck, Australian National University Canberra, Australia
Citation: Chris Kennard
1130 - 1230
1A Plenary Session 4: Navigating Neurological Differences
Chairs: Simon Hickman & Biba Stanton
1130 Dizziness, balance and PPPD: Diego Kaski, UCLH, London
1200 Understanding autism: Francesa Happé, King’s College, London
1230 - 1400
Lunch, Exhibition & Sponsored Symposia
1245 – 1345
Sponsored Symposia sessions:
1C Angelini Pharma Service design in neurology: A case study in epilepsy
3A Argenx Redesigning Myasthenia Gravis care: Innovative pathways and patient-centric approaches to care
3B AbbVie The Migraine movement – collaboration, innovation and access beyond secondary care
1400 - 1510
1A Plenary Session 5: Appraising New Therapies
Chairs: Anish Bahra & Timothy Rittman
1400 The power of placebo in headache trials: Elizabeth Loder, Harvard Medical School, Boston, USA
1440 Using new treatments for Alzheimer’s: Paresh Malhotra, Imperial College, London
1510 - 1610
2A Poster Session 2
Group 2: Epilepsy
Chairs: Joseph Anderson & Lina Nashef
Group 4: Headache
Chairs: Mark Weatherall & Nick Silver
Group 6: Movement Disorders
Chairs: Thomasin Andrews & John Janssen
Group 8: Neuromuscular
Chairs: Aisling Carr & Channa Hewamadduma
Group 10: QST
Chairs: Amy Ross Russell & Barry Seemungal
1610 - 1650
2A Coffee, Exhibition & Silent Symposium: Roche
1650 - 1800
Parallel Sessions
1A Parallel Session 3: MS/Inflammatory
Chairs: Ahmed Mubarak Mohamed & Tom Hayton
1650 ABN Fellow presentation: High-Throughput Single Cell Multi-omic Analysis of Multiple Sclerosis Patient Blood to Identify Causal Immune Cell Subsets: Redwan Farooq
1701 Diagnosing multiple sclerosis using the central vein sign: validating the proposed lesion assessment criteria: Margareta Clarke
1712 Perception of risks and attitudes towards screening for multiple sclerosis: Isobel Hodge
1723 Pregnancy and Post-partum Outcomes in Multiple Sclerosis: Insights from the UK MS Pregnancy Register: Mariana Nalmpanti
1734 Chronic presentation of antibody mediated transverse myelitis: Chiara Rocchi
1745 Transcriptional risk scores identify subgroups of multiple sclerosis patients more accurately than polygenic risk scores: Matthew Upcott
1C Parallel Session 4: Neuromuscular
Chairs: Katy Dodd & Dipa Jayaseelan
1650 ABN Fellow presentation: Phenotypic and immunobiological features of herpes simplex virus encephalitis and post-infectious antibody-mediated disease: Jonathan Cleaver
1701 Fluid biomarkers in chronic inflammatory neuropathies: comparative analysis and evaluation of diagnostic utility: Roberto Bellanti
1712 Clinical Practice Guide: Triple M syndrome/ICI-related myocarditis, myositis, myasthenia: Aisling Carr
1723 Genetic Testing in Motor Neurone Disease (MND) Clinic: Audit of clinical effectiveness and patient experience: Clare Galtrey
1734 Autonomic Phenotype and Cutaneous Innervation in Ganglionic Acetylcholine Receptor Positive and Negative Autoimmune Autonomic Ganglionopathy: Junie Shiwen Koay
1745 HTLV-1 associated myositis: A case series: Michael Wride
1930
Titanic Hotel Gala Dinner
Friday 9 May
0700 - 0740
0750 - 0850
Yoga / 5k Fun Run / Waterfront Walk
Special Interest Group Sessions:
1A Cognitive
1C Autonomic
3A FND
3B Neuro-oncology
0900 - 0945
1A AGM
0945 - 1030
1A President’s Lecture: Neil Robertson, Cardiff
1030 - 1115
2A Coffee & Exhibition
Alnylam Silent Symposium: hATTR Amyloidosis with Polyneuropathy (hATTR-PN): Red flags not to miss, rapid single gene testing, and real world experience from the UK
1115 - 1215
1A Case Presentation Competition
Chairs: Emma Tallantyre & Trevor Pickersgill
1115 Robin Brown
1125 Dhruv Bansal
1135 Nazifa Ullah
1145 Alex Wallace
1155 Rebecca Johnson
1205 Kiran Pillai
1215 - 1300
1A CPC
Roswell Martin, Gloucester Royal Hospital, Gloucestershire
Chair: Richard Davenport
1300 - 1430
Lunch, Exhibition & Sponsored Symposia
1315 – 1415
Sponsored Symposia sessions:
1C Teva (Tardive dyskinesia)
3A Merck New Perspectives in MS: The evolving landscape for the diagnosis, monitoring and treatment of MS
3B Pfizer Gepants beyond the pivotal trials: emerging real-world evidence and migraine clinical conundrums
1430 - 1540
Parallel Sessions
1A Parallel Session 5: Movement Disorders
Chairs: Antonella Macerolllo & Ralph Gregory
1430 ABN Fellow presentation: The Pathophysiology of Myelin Oligodendrocyte Glycoprotein Antibody Disease: Trisha Mukherjee
1441 FGF14 GAA repeat expansions in multiple system atrophy: Viorica Chelban
1452 Illusions of Self-Motion as a Predictor of Tremor Control and Balance Outcomes Following MRgFUS Thalamotomy: Jivan Mann
1503 Perception vs. Practice: The reality of Functional Neurological Disorder diagnosis at a large neurological centre: Edward Nicholas
1414 Botulinum Toxin and Deep Brain Stimulation in Dystonia: Stephanie Ong
1425 The Incidence, Prevalence and Survival of Frontotemporal Lobar Degeneration Syndromes: 10 years of ‘PiPPIN’: Katherine Stockton
1C Parallel Session 6: QST
Chairs: Alakendu Sekhar & Lucy Kinton
1430 ABN Fellow presentation: Clinically silent MRI lesions in RRMS: prognostic impact and an emulated trial of disease modifying therapy escalation: Cyrus Daruwalla
1441 GP Direct MRI Access’s impact on Hampshire’s Neurology Services: Simplifying care or Bottlenecks?: Naznin Bipasha
1452 Analysis of Urgent referrals to Neurology via the 2-Week Wait Pathway for suspected CNS malignancies: Ayush Mohan
1503 Epidemiology of neurological conditions in a large urban conurbation: Rohan Ahmed
1414 Patients with neurological or psychiatric complications of COVID-19 have worse long-term functional outcomes: COVID-CNS-study: Rajish Shil
1425 Gamma Knife Radiosurgery increases risk of Immunotherapy-related adverse events in patients with cerebral metastases: Fred van Someren
1540 - 1615
2A Coffee & Exhibition
Alnylam Silent Symposium: hATTR Amyloidosis with Polyneuropathy (hATTR-PN): Red flags not to miss, rapid single gene testing, and real world experience from the UK
1615 - 1715
1A Plenary 6: Video Session
Chairs: Jan Coebergh & Hadi Manji
1615 Movement Disorders: Mark Edwards, King’s College, London
1645 Dystonia/ jerks/tics/ataxia: Tom Warner, UCLH, London
1715 - 1730
1A Prize announcement & Close: Neil Robertson, ABN President